Immunopathology of inflammatory bowel disease

Kori L Wallace, Li-Bo Zheng, Yoshitake Kanazawa, David Q Shih

Abstract

Inflammatory bowel disease (IBD) results from the complex series of interactions between susceptibility genes, the environment, and the immune system. The host microbiome, as well as viruses and fungi, play important roles in the development of IBD either by causing inflammation directly or indirectly through an altered immune system. New technologies have allowed researchers to be able to quantify the various components of the microbiome, which will allow for future developments in the etiology of IBD. Various components of the mucosal immune system are implicated in the pathogenesis of IBD and include intestinal epithelial cells, innate lymphoid cells, cells of the innate (macrophages/monocytes, neutrophils, and dendritic cells) and adaptive (T-cells and B-cells) immune system, and their secreted mediators (cytokines and chemokines).

Either a mucosal susceptibility or defect in sampling of gut luminal antigen, possibly through the process of autophagy, leads to activation of innate immune response that may be mediated by enhanced toll-like receptor activity. The antigen presenting cells then mediate the differentiation of naive T-cells into effector T helper (Th) cells, including Th1, Th2, and Th17, which alter gut homeostasis and lead to IBD. In this review, the effects of these components in the immunopathogenesis of IBD will be discussed.

Key words: Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Microbiome; Autophagy; Th helper 17; Innate immune system; Adaptive immune system; Innate lymphoid cells; TL1A

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic inflam-
inflammatory disorder that is comprised of both Crohn’s disease (CD) and ulcerative colitis (UC), and is characterized by alternating phases of clinical relapse and remission. CD can affect any part of the gastrointestinal tract and classically presents with fatigue, prolonged diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. UC characteristically involves the colon and presents with symptoms that usually rectal bleeding, frequent stools, mucus discharge from the rectum, tenesmus, and lower abdominal pain. IBD is thought to be the result of a dysregulated immune system in the context of a genetically susceptible individual. Currently, IBD affects 1.4 million Americans and at a prevalence rate of 396 per hundred thousand individuals worldwide[1]. The incidence of CD in the United States is estimated to be 5 per hundred thousand persons and is characterized by focal and transmural inflammation that can occur anywhere along the length of the gastrointestinal system, that may include B2 strictureing (gut luminal narrowing), B3 penetrating (bowel perforation, fistula, inflammatory mass/abscess), and with possible perianal disease[2,3]. UC affects 8-12 per hundred thousand individuals and is characterized by colonic mucosal inflammation along the entire colon and involving the rectum[4,5]. Also, patients with IBD have an increased risk of developing other chronic inflammatory disorders, such as psoriasis and primary sclerosing cholangitis[6].

The exact cause of IBD is still unknown, but is thought to be due to a combination of a patient’s genetics, microbiome, immune response, and the environment that result in an excessive and abnormal immune response against commensal flora in genetically susceptible individuals. Epidemiological data suggest an association between IBD and a number of environmental factors, such as antibiotic use, microbial exposure both early and late in life, and possibly diet[7,8]. The genetics of IBD are complex and thought to be polygenic. Genome-wide association studies (GWAS) suggest that dysregulation in innate and adaptive immunity contribute to the development of IBD. Susceptibility variants have been reported in genes associated with autophagy (ATG16L1), the interleukin (IL)-23/Th17 pathway (IL-12B), TGF-beta pathway (SMAD3), T-cell activation (TACI), among other immune system genes[9,10,11].

The identification of these and other loci is part of a larger picture that aims to understand how polymorphisms in these genes can lead to an increased risk of developing IBD. Here we review the available evidence supporting the role of the microbiome and the innate and adaptive immune responses and their crosstalk in IBD.

THE MICROBIOME

Overview

The interaction of the host with its abundant microbiota is complex. The luminal surface of the small and large intestine, approximately 300-400 m², is a unique environment where an enormous population of bacteria exists in close proximity to the immune system of the gut mucosa. This roughly translates to the interactions of 10³⁰ microorganisms per gram of feces with 10⁰ immune cells per gram of enteric tissue[12]. A complex network of interactions exists between gut epithelial cells, immune cells, and foreign bodies that transition along the gut. Functionally, the gut-associated lymphoid tissues generates either an immune response for rejection of pathogens or a clinical immune response of tolerance for dietary and microbial antigens[13]. Data supports the hypothesis that IBD results from a dysregulated immune response to the microbiota. It was found that in CD patients, diversion of feces induces inflammatory remission and mucosal healing in the downstream intestinal segment and infusion of feces reactivates the disease[14]. Furthermore, in UC patients with active disease, treatment with broad-spectrum antibiotics reduced mucosal inflammation[15]. These data support the concept that luminal bacteria provide the stimulus for an inflammatory response leading to mucosal injury. Two main hypotheses have been suggested that might contribute to the loss of tolerance towards the indigenous microbiota in patients with IBD. First, genetic susceptibility leads to a dysregulation of the mucosal immune system that result in excessive immunologic responses to normal flora. Second, an imbalance exists in the composition of the microbiota that elicits a pathologic response from the normal mucosal immune system[16]. In all likelihood, it probably is a combination of both hypotheses.

Advancements in genetic technology, such as 16S ribosomal RNA (rRNA) gene and metagenomic sequencing have allowed researchers to determine the composition of the microbiome[17]. Recently, a number of studies have profiled the “normal” human gut microbiota. Briefly, it is thought that greater than 90% of all phylotypes belong to two divisions, Bacteroidetes and Firmicutes[18]. Other divisions that have consistently been recovered from “normal” individuals include Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia. It is believed that the composition of fecal microbiota remains relatively constant over time, termed resilience, with temporary changes occurring after exposure to food, medicine, and physical environment[19]. In 2010, whole-genome shotgun sequencing revealed 3.3 million nonredundant microbial genes in fecal samples from an adult European cohort[20]. It was found that up to 98% of the genes were bacterial with the rest belonging to archaea, yeasts, viruses, and protists. The three most abundant genera in the fecal samples were Bacteroides, Faecalibacterium, and Bifidobacteria, however the percent composition was found to be highly variable between individuals[21]. Three main enterotypes (independent of gender, age, race, body mass index, or country and continent of residence) were created that are classified based upon the prominent genera represented: enterotype 1-Bacteroides, enterotype 2-Prevotella, enterotype 3-Ruminococcus[22].

Individuals with IBD have been shown to have changes in the bacterial composition of feces with less bacterial
diversity, having fewer numbers of non-redundant bacterial genes, as compared to healthy controls\[16,23\]. Adding to the complexity, the bacterial profile also differs between individuals with UC and CD. In a twin study, twins with UC were found to have less Bacteroides and more Actinobacteria and Proteobacteria than their healthy twin counterparts. The decrease in Bacteroides was made up for by an increase in the Prevotellaceae family\[26\]. Also, it has been found that Escherichia coli (E. coli) is to be increased in fecal samples from individuals with UC, with some isolates expressing virulence factors and invading properties\[17-28\]. Dysbiosis also exists in CD. Many studies have shown a decrease in the abundance of several bacterial species of the phylum Firmicutes in patients with CD\[29,30\]. Also, the microbiome of individuals with CD predominately in the ileum was found to differ from those whose disease was found predominantly in the colon. Those with ileal CD had decreased Faecalibacterium and Roseburia and increased amounts of Enterobacteriaceae and Ruminococcus granulatus\[31\]. Consistent with what is seen in UC patients, E. coli also has been observed in patients with CD\[27\].

Recently a new pathogenic group called adherent-invasive E. coli (AIEC) has been isolated from the ileum of CD patients\[30,32\]. Darfeuille-Michaud\[33\] have accumulated a large body of data showing that AIEC is able to invade epithelial cells and to survive and replicate within macrophages and is associated with ileal mucosal CD pathogenesis. They found that AIEC was present in the inflamed ileum of 22% of chronic CD patients, as compared to only 6% of control patients, as well as 36% of the newly formed terminal ilea of postsurgical CD patients\[34\]. However, AIEC was found in only a small percentage of affected colons of CD patients and in zero percent of UC patients, suggesting that AIEC strains are associated specifically with ileal mucosa in CD\[35\]. AIEC facilitate binding and invasion into epithelial cells via type 1 pili and flagella\[35\]. This interaction is dependent upon epithelial expression of CEACAM6, which is a carcinoembryonic antigen upregulated by inflammatory cytokines and possibly by AIEC itself\[35\]. Furthermore, transgenic mice overexpressing CEACAM6 in epithelial cells are colonized by AIEC and manifest gut inflammation with marked neutrophil infiltration and ulceration\[17\]. In the lamina propria, AIEC is taken up by macrophages and can survive and proliferate within macrophage vacuoles, which suggest that the bacteria is not readily cleared from the site and may represent a defect in autophagy\[36,37\].

Also, recently an important role of fungi in gut homeostasis has been found. Besides the massive amount of bacteria known to make up the intestinal microflora, the mammalian gut also contains a rich fungal community that interacts with the immune system via Dectin-1, which is a pattern-recognition receptor expressed by innate immune cells, such as: macrophages, dendritic cells (DCs), and neutrophils\[38\]. It was found that mice deficient in Dectin-1 exhibited increased susceptibility to dextran sulfate sodium (DSS) colitis that was the result of an altered response to the host’s fungi\[41\]. Furthermore, polymorphisms in the gene for Dectin-1 have been shown to be strongly linked to a severe form of UC\[41\]. This data suggests that the interactions between fungi and the innate immune system are important in the development of IB. Viral infections also impact the gut microflora. In mice, virus-plus-susceptibility gene interactions have been shown to induce colitis that mimics CD. When mice with a specific mutation in a CD susceptibility gene for autophagy (ATG16L1) were infected with murine norovirus they displayed abnormal Paneth cell structure and granule packaging similar to those seen in CD patients homozygous for the risk allele of ATG16L1\[42\]. These changes were not seen in control mice nor in CD patients homozygous for the nonrisk allele of ATG16L1. Furthermore, when these mice were treated with DSS they displayed worse colitis than control animals\[43\]. These results demonstrate how a genetic factor and an environmental agent can contribute to the pathogenesis of CD. Also, HIV infection of humans and simian immunodeficiency virus (SIV) infection of rhesus monkeys is known to cause systemic immune activation and associated with damage to the intestinal epithelium and translocation of antigens into the blood\[44-48\]. Pathogenic SIV infection has been associated with significant expansion of the enteric virome, including adenovirus and parvovirus, that can lead to enteritis without changes in the microbiome\[44]. This data suggests that the enteric virome might contribute to AIDS pathogenesis by damaging the intestinal epithelium to allow translocation of microbes and viral antigens into the circulation.

The consequences of these shifts in microbiota are unclear, particularly whether it is cause or effect. Regardless of the inciting cause of IB, it is apparent that the host-microbiome interaction plays a large part in disease pathogenesis.

**Host-microbial interactions**

Host-microbe interactions are crucial in the development and modulation of the immune system and protection from pathogenic bacterial invasion. The first line of defense to pathogenic organisms is the innate immune system, which in the gut consists of mucin, the epithelium, and cells of the innate immune system (i.e., neutrophils, DCs, monocytes/macrophages, and innate lymphoid cells (ILCs)). Interestingly, mice lacking an adaptive immune system, but that have an intact innate immune system, such as recombinase activation gene deficient (RAG-1) and severe combined immunodeficient (SCID) mice, do not develop spontaneous colitis and co-exist with the microbiota. However, these mice can develop colitis when induced by DSS, anti-CD40 antibody, and Helicobacter hepaticus infection\[46-49\]. These data suggest that in the absence of an adaptive immune system, the innate immune system is sufficient for the development of IB. However, the adaptive immune system is still thought to play an important role in the development of IB, as RAG deficiency can prevent the development of spontaneous
secretors. Twenty percent of the population are non-secretors, which has been associated with a variety of illnesses including recurrent norovirus and encapsulated bacterial infections, duodenal ulcerations, and susceptibility to CD.[50-59]. The inability to secrete H1 into the mucosa is thought to affect how commensal and pathogenic flora interact with the epithelial layer and may interfere with the ability of the commensal flora to adhere, which could result in increased susceptibility to infection, invasion, and activation of the immune system.

The epithelium
The epithelium of the intestine has many functions, including absorption, secretion, and digestion. There are four main types of epithelial cells: one, absorptive enterocytes; two, mucus producing goblet cells; three, hormone producing enteroendocrine cells; and four, antimicrobial and growth factor producing Paneth cells (Figure 1). The epithelium forms a mucosal barrier with tight junctions between enterocytes that can exclude the entry of most substances. The epithelial layer is renewed every 2-3 d with a balance of proliferation of epithelial cells in the crypts and migration down the villi in the small intestine or onto the surface of the colon and apoptosis and shedding of the enterocytes. Disruption of this process im-

Figure 1 Innate immune system responses in the gut. The intestinal epithelial barrier is equipped with several layers of defense mechanisms to limit luminal antigen translocation. Goblet cells, Paneth cells, and enterocytes secrete mucins and antimicrobial peptides that assemble into a mucus layer. Innate immune system cells, such as macrophages and dendritic cells, can sense invading bacteria through extracellular and intracellular pattern recognition receptors (Toll-like receptors-TRLs and NOD-like receptors-NLRs) and initiate rapid inflammatory responses mediated by the secretion of cytokines and chemokines. Innate lymphoid cells (ILCs) are also found in the lamina propria where they contribute to cytokine production and inflammatory cell recruitment.
pairs the epithelial integrity and can result in chronic inflammation. Defects in epithelial integrity may contribute to IBD pathogenesis by allowing free passage of organisms across the epithelial layer where they can incite an immune response. For example, mutations in the organic cation transporter (OCTN) gene, which is involved in the transport of cationic proteins, such as amino acids and nutrients, lead to an increased susceptibility to CD. The susceptibility is thought to result from impaired fatty acid oxidation, which can cause colitis in experimental models in the setting of bacterial antigen exposure.

The epithelium lies between the immune cells in the lamina propria and the microbiota in the gut lumen and functions to communicate with both. For example, the microbiota signals enterocytes as well as innate cells in the lamina propria via pattern recognition molecules signal receptors, such as toll like receptors (TLRs) and cytosolic NOD-like receptors (NLRs) (Figure 1). These signals have been shown to be necessary for normal homeostasis and resistance to injury. Cytokines, such as interferon (IFN)-γ, interleukin (IL)-17, and IL-22, pathogens, and commensal bacteria have substantial effects on the epithelium by regulating barrier integrity and function. Expression of pattern recognition receptors is highly regulated to prevent an inappropriate immune response, but still allow for constant surveillance. Mutations in genes coding for these receptors have been found to be IBD susceptibility genes. Haplotypes of the TLR8 gene can confer protection (H1) or risk (H4) to the development of IBD. Agonists of TLR8 have been shown to cause downstream activation of proinflammatory cytokines such as IFN-γ, IL-12, and tumor necrosis factor (TNF)-α in peripheral blood mononuclear cells. The TLR9 gene is also a CD and UC susceptibility gene. It has been shown that mice infected with Campylobacter jejuni (C. jejuni) or TLR9 agonists have increased susceptibility to mild DSS colitis via a mechanism involving secretion of CXCL8.

Defects in the intestinal barrier can lead to persistent immune activation and has been suggested to play a role in IBD. Normally, translocation allows small amounts of luminal antigens to pass transcellularly across the epithelium either through receptor-mediated endocytosis or non-selective endocytosis. A small amount of bacteria is normally allowed to translocate and allows for physiologic sampling of luminal content by the host's immune system. Animal models that lack components of a healthy epithelial barrier have been shown to develop IBD. Expression of dominant-negative N-cadherin in mouse intestinal epithelium has been shown to lead to CD-like symptoms. NOD2 is a protein that acts as an intracellular pattern recognition receptor for muramyl dipeptide (MDP), a component of the bacterial wall peptidoglycans. Mice lacking intracellular pattern recognition receptors, NOD1 and NOD2, were shown to have decreased E-cadherin expression with increased epithelial permeability and decreased antimicrobial production. NOD2 was one of the first CD susceptibility genes, with homozygous mutations found in 15% of patients with CD. Mutations in NOD2, as well as other pattern recognition receptors, might impair the ability of the mucosal immune system to sense organisms thereby leading to defective microbial clearance and persistent antigenic stimulation. This in turn may result in mucosal inflammation and loss of regulatory control over proinflammatory pathways, which could possibly lead to the development of IBD.

**AUTOPHAGY**

The term autophagy, or “self-eating,” results in the lysosomal degradation of organelles, unfolded proteins, or foreign extracellular material (Figure 2). It is a key process required for maintaining cellular homeostasis after infection, mitochondrial damage, or ER stress. Defects in autophagy have been shown to result in pathological inflammation and GWAS have linked two key genes in autophagy, ATG16L1 and IRGM, to CD. An ATG16L1 hypomorphic mouse line that expresses about 1% of the normal level of ATG16L1 was shown to have Paneth cell granule abnormalities that are similar to those found in ileal resections in patients with CD that also carry the ATG16L1 gene variant. While these hypomorphic ATG16L1 mice do not develop spontaneous colitis, they were found to have an increased susceptibility to DSS colitis. However, when rederived virus free, these mice lost the Paneth cell pathology and ability to develop DSS induced colitis, which could be reversed by norovirus infection. A recent study has reported that the ATG16L1 and NOD2 pathways may be interrelated. In 2010, Cooney et al. demonstrated that NOD2 stimulation is capable of initiating autophagy in DCs and that for effective autophagy to occur, both intact NOD2 and ATG16L1 functions are required. IRGM belongs to a family of interferon-inducible immunity related GTPases (IRGs) that encodes a protein involved in multiple autophagic pathways including intracellular clearance of pathogens. IRGM has been shown to play a role in autophagy during both Salmonella typhimurium and Mycobacterium bovis infections. Another study in CD patients has demonstrated that autophagy is also important in the clearance of AIEC and that IRGM and ATG16L1...
deficient cells had increased AIEC replication, suggesting that these genes play a significant role in clearance of this organism and intestinal inflammation[39]. These studies implicate that autophagy plays an important role in human inflammatory disorders by direct elimination of intracellular bacteria and activation of pattern recognition receptor signaling which is involved in gut homeostasis and CD pathogenesis.

**INNATE AND ADAPTIVE IMMUNITY**

**Overview**

The immune system has evolved as protection against a wide range of infectious agents. In vertebrates, the immune system is broadly divided into two effector classes, the innate and adaptive immune responses. The innate immune system is the first line of defense and provides an immediate protective response against infections and also helps to initiate the adaptive immune response (Figure 1). The innate immune system is non-specific and does not confer lasting immunity (memory). The innate immune system is comprised of the epithelial barrier, macrophages, monocytes, neutrophils, DCs, and natural killer cells (NK cells), eosinophils, and basophils. These cells act together to initiate inflammation by secreting cytokines, chemokines, and antimicrobial agents. This leads to phagocytosis of infected cells and microorganisms, antigen presentation, and activation of the adaptive immune system.

The adaptive immune response is comprised of lymphocytes (T and B cells) that when activated generate effector responses (cytokines and antibodies). In contrast to the innate immune system, the adaptive immune system is highly specific and confers long lasting immunity (memory). It is generally thought that the adaptive immune system is the main contributor to disease pathogenesis in IBD, either through increased proinflammatory cytokines driven by the T-helper (Th) subsets or by ineffective anti-inflammatory regulatory T-cells (Tregs). Naïve T-cells (Th0) cells after activation are able to differentiate into Th1, Th2, or Th17 cells (Figure 3). In particular, Th1 responses have been thought to drive the pathogenesis of CD, while UC is thought to be driven by Th2 responses. Recent advancements suggest that other cells, such as ILCs and Th17 cells, have emerged as important contributors to IBD pathogenesis.

**Role of innate lymphoid cells in IBD**

Until recently NK cells were thought to be the only innate cell derived from a lymphoid progenitor. However, recent developments have classified NK cells as a subset of a new family of hematopoietic effector cells called ILCs. ILCs are an emerging and diverse group of immune cells and are part of the new frontier of immunology research. All ILCs derive from an Id2 expressing progenitor and are defined by three main features: One, they are of lymphoid morphology; two, they are cell lineage negative (CD3, B220, GR1, CD11b, Ter119); and three, they lack RAG-dependent antigen receptors (Figure 4)[81]. Recently, a unifying ILC classification system has
based upon phenotypic and functional characteristics has been proposed (Table 1)\(^8\). ILCs can be classified into three groups: Group 1 ILCs, which are T-box dependent and are comprised of ILC1 and NK cells; group 2 ILCs, which are GATA-binding protein 3 (GATA3) and retinoic acid receptor-related orphan receptor (ROR) dependent, and comprised of ILC2s; and group 3 ILCs, which are RORγt dependent and are comprised of ILC3s and lymphoid tissue-inducer (LTi) cells\(^8\).

The key cytokines secreted by ILCs tend to mirror those secreted by the T-helper cells of the adaptive immune system and therefore ILCs have been thought of as the innate counterparts of T-helper lymphocytes (Table 1). Group 1 ILCs are defined by their ability to produce Th1 cell associated cytokines, in particular IFN-γ. Although under debate, the prototypical cell is the NK cell. Group 2 ILCs are defined by their ability to produce Th2 cytokines, in particular IL-5 and IL-13 and the prototypical cells are the IHL2 cells or nuocytes\(^8,9\). These cells have been shown to play a major role in defense against parasites and in allergy and asthma\(^9,10\). Group 3 ILCs are defined by their ability to secrete Th17 like cytokines such as IL-17 and IL-22 and the prototypical cells are LTi cells\(^11\). Group 3 ILCs have been shown to play a major role in autoimmune disease and have been shown to mediate colitis in a mouse model of IBD\(^12\).

Since ILCs have been shown to be important in mucosal immunity it was only logical to examine the role of these cells in IBD. Recent data has implicated ILCs, in particular group 3 ILCs in the development of IBD. While most research into IBD has focused on the role of the adaptive immune system, in particular Th1 and Th17 subsets, as well as ineffective regulatory T-cells, new evidence suggests that IBD can be triggered in RAG-/- mice, which lack all components of the adaptive immune system in an IL-23 dependent manner. Buonocore et al\(^13\) demonstrated that group 3 ILCs, and not NK cells (group 1 ILCs), were increased and produced large amounts of IL-17 and IFN-γ after *Helicobacter* infection in RAG-/- mice were required for colitogenesis. Accumulating evidence suggests that group 3 ILCs induce colitis via an IL-23R-22 dependent mechanism\(^14\). RAG-/- mice can also develop colitis after injection of CD40L. Vonarbourg et al\(^15\) demonstrated that CD40L induced colitis requires the presence of innate lymphocytes because CD40L...

---

**Figure 4** Development and classification of innate lymphoid cells\(^8\). Innate lymphoid cells (ILCs) all derive from an ID2 positive progenitor cell. Group 1 ILCs make interferon (IFN)-γ. Group 2 ILCs produce IL-5 and interleukin (IL)-13. Group 3 ILCs produce IL-17, IL-22, and IFN-γ. NK require IL-15, whereas all other ILCs require IL-7 for development. Group 2 ILCs depend on transcription factors GATA3 and ROR for development. Group 3 ILCs require RORγt for development. Also, subsets of group 3 ILCs require additional transcription factors, such as aryl hydrocarbon receptor (AHR) for development. NK cells, which are group 1 ILCs, require both T-bet and eomesodermin (EOMES). The mechanisms of ILC1 development are not fully elucidated, however are known to require transcription factor T-bet for development.
Th17 cells: Friend or foe

Th17 cells are a subset of helper T-cells that are induced by IL-6 and TGF-B, expanded by IL-23, and characterized by the secretion of copious amounts of IL-17A, IL-17F, IL-21, and IL-22. Th17 cells are a subset of helper T-cells that are induced by IL-6 and TGF-B, expanded by IL-23, and characterized by the secretion of copious amounts of IL-17A, IL-17F, IL-21, and IL-22. Th17 and Th1/Th17 cells produce both IFN-γ and IL-17 cytokines, which mediate different immune responses. Th17 cells are characterized by the expression of the transcription factor RORt, which is involved in their differentiation and expansion.

ILCs: Innate lymphoid cell subsets

| ILCs | Lineage | Mouse | Human | Cytokines | Function | Disease |
|------|---------|-------|-------|-----------|----------|---------|
| Group 1 | ILC1s | LinThy1/Scal1/Tbet | LinCD56/NKp46/NKp30/NKp44 | IFN-γ | Inflammation | IBD? |
| NK cells | NKp46/NK1.1/CD122 NKG2D/CD161/CD16 | CD122/NKG2D/CD161/KIR | IFN-, TNF-α, cytotoxic effectors | Immunity to viruses and intracellular pathogens, tumor surveillance | Inflammatory conditions, IBD |
| Group 2 | ILC2s | LinICOS/Thy1/Scal1 IL-7R/GAT2 | LinICOS/Thy1/Scal1 | IL-5, IL-9, IL-13 | Immunity to helminthes, wound healing | Allergy, asthma |
| Group 3 | ILC3s | LinThy1/Scal1/RORγ NKp46/IL-7R | CD56/NKp46/NKp30/NKp44 | IL-22 | Lymphoid tissue development, intestinal homeostasis, immunity to extracellular bacteria | IBD |
| LTi cells | LinThy1/Scal1/RORγ NKp46/IL-7R | IL-7R/CD45/RORγ | IL-17A, IL-17F, IL-22 | Homeostasis of epithelia, immunity to extracellular bacteria | IBD |

Lin-: Lineage marker negative (mouse negative for CD3, CD19, B220, CD11b, Gr1, Ter11; human negative for CD1a, CD3, CD11c, CD34, CD123, TCR, TCR, CD19, CD14, CD16). IBD: Inflammatory bowel disease; ILC: Innate lymphoid cell; IFN: Interferon; TNF: Tumor necrosis factor; NK: Natural killer.

Injection into RAG2-/-IL-2Rγ-/- mice, which lack both adaptive immune cells and ILCs, did not develop colitis. Furthermore, group 3 ILC involvement in IBD has been further supported by the observation that RORt-/- mice do not develop CD40L induced colitis[37]. In an elegant set of experiments, it was found that LTi cells were the subset of group 3 ILCs that were colitogenic and required for disease onset, suggesting an important role for these cells in IBD pathogenesis[39]. In individuals with CD, a population of innate lymphocytes that were RORt- and represent human ILCs were found to be increased in the lamina propria compared to controls and this increase was IL-23 dependent[30,31]. Although a young field, data suggests that group 3 ILCs are an important cell type to study for answering questions about the pathogenesis of IBD as well as possible future therapies.
to be characterized by their production of IFN-γ and by the expression of specific surface markers, including IL-18R1 and CXCR3\(^{[127]}\). IL-17A deficient mice or those treated with neutralizing antibodies to IL-17A or IL-17RA are resistant to the development of RA and EAE\(^{[128,129]}\). Furthermore, in a trinitrobenzene sulfonic acid (TNBS) mouse model of colitis IL-17RA deficient animals were protected from the development of acute mucosal inflammation\(^{[130]}\). However, in a DSS model of colitis, mucosal inflammation was ameliorated by IL-17F deficiency, but exacerbated by IL-17A deficiency, suggesting an important role for IL-17F and perhaps an alternative role for IL-17A\(^{[131-133]}\). Furthermore, supporting a protective role for IL-17A, it has been shown that IL-17A directly inhibits Th1 cells and suppresses development of inflammation\(^{[134]}\). Additionally, anti-IL-17A monoclonal antibody treatment was shown to exacerbate DSS induced colitis\(^{[135]}\). These studies suggest that IL-17A may protect against the development of mucosal inflammation whereas IL-17F may drive it.

As demonstrated by the data above, the biology of IL-17 deficiency has been complicated, with some studies showing a pathogenic role, while others suggesting a protective role. However, there has been a significant amount of data suggesting that IL-17A has played a pathogenic role in IBD. Therefore, a double-blind, randomized, placebo-controlled study tested whether the anti-IL-17A monoclonal antibody, secukinumab, would be beneficial in CD patients\(^{[136]}\). Surprisingly, the study found that blockade of IL-17A was ineffective and caused a higher rate of adverse events as compared to placebo, suggesting a protective role of IL-17A\(^{[137]}\). Although the study was halted prematurely, exploratory analysis of CD candidate genetic polymorphisms found that a subset of patients with a minor allele of TL1A actually had an improved clinical score over the course of the treatment\(^{[138]}\). These data suggest that in the right genetic context, secukinumab therapy may be beneficial to some patients, which further supports the concept of treating each individual with IBD based upon their own genetic composition.

TL1A: CONNECTING THE INNATE AND ADAPTIVE IMMUNE SYSTEM

Tumor necrosis factor super family 15 (TNSF15) encodes the protein TL1A, a member of the TNF superfamily, is expressed either membrane bound or secreted by monocytes, macrophages, DCs, fibroblasts, and endothelial cells in response to stimulation by cytokines and microorganisms\(^{[139-140]}\). It binds to death domain receptor 3 (DR3), mainly expressed on T-cells, to initiate a number of immune responses, such as activation of T-cells resulting in the secretion of proinflammatory mediators\(^{[141]}\). TL1A has been implicated in the pathogenesis of many autoimmune diseases, including asthma, rheumatoid arthritis, and IBD\(^{[96,146,142-144]}\). Numerous studies have supported the concept that TL1A is a major regulator of mucosal inflammation at the interface between the innate and adaptive immune system\(^{[145-147]}\).

In 2005, in a study of Japanese CD patients, polymorphisms in the TNSF15 gene was identified as having a strong association with CD\(^{[148]}\). This association has been reproduced in other studies, including European and Jewish CD and UC patients, and has been demonstrated to be the dominant gene in East-Asians with IBD\(^{[121-149,153]}\). Haplotypes within the gene confer either risk or protection, which is dependent upon the ethnicity of the individual. In non-Jewish CD patients, haplotype A is a risk allele, while haplotype B is protective\(^{[146,150-153]}\). However, in Jewish CD patients, haplotype B has a trend towards risk, as these patients had worsened disease as manifested by higher incidents of surgery and increased responses to E. coli outer membrane porin C (OMPC)\(^{[154,155]}\). Furthermore, monocytes isolated from Jewish patients that were haplotype B secreted increased amounts of TL1A than haplotype A carriers after stimulation\(^{[156]}\).

Given the information generated from the human GWAS studies, transgenic mice have been created that overexpress TL1A. In 2011, Meylan et al\(^{[147]}\) and Taraban et al\(^{[148]}\) found that murine colitis driven by TL1A overexpression in T-cells and DCs was found to be dominated by a Th2 response over Th1, with elevation in IL-13 and unchanged levels of IFN-γ. Also, in both models, spontaneous intestinal inflammation developed, with disease severity being greatest in the terminal ileum and correlating to transgene expression level. This observation was abolished with anti-IL-13 treatment. Shih et al\(^{[143]}\) reported similar observations in another model of TL1A overexpression. However, they also found that these mice had increased levels of IFN-γ and intestinal fibrosis. The differences in these mouse models may be secondary to differences in the generation of the mice and/or different gut microflora between animal facilities. Regardless, all models demonstrated intestinal inflammation and this supports evidence of TL1A polymorphisms being associated with IBD. Given this information, studies utilizing anti-TL1A antibodies were undertaken. In models of TNBS and DSS colitis anti-TL1A neutralizing antibody treatment was shown to ameliorate weight loss and intestinal inflammation\(^{[146,157]}\). These studies suggest a role for using blocking antibodies to TL1A to ameliorate pathological T-cell responses in IBD.

CONCLUSION

In current immunology there are new Th cell subsets, such as IL-9 producing Th9 cells, IL-22 producing Th22 cells, follicular helper T-cells, and emerging types of Treg cells that are now also all being implicated in the pathogenesis of IBD\(^{[158-161]}\). Furthermore, historically it was thought that terminally differentiated Th cells seldom re-differentiate to other Th subsets, however now the plasticity between Th cells is now extensively under investigation\(^{[162]}\).

It has been well documented that the adaptive im-
mune system plays an important role in the development and perpetuation of the inflammatory cascade in IBD. In particular, T-cells have been shown to be key players in driving intestinal inflammation. However, a number of unresolved issues exist that need to be addressed in order to develop successful and appropriate therapeutic strategies. Recent advances have clarified the importance of the innate immune system in IBD pathobiology. Furthermore, besides anti-TNF agents, molecules targeting specific T-cell derived molecules have largely failed. This is likely due to the complexities and redundancies of cytokine networks and highlights how different each individual's immune system is in the context of their own genetics. The studies of the interactions between the different components of the innate and adaptive immune system, as well as the interactions with the intestinal microbiota, and how these interactions relate in the overwhelming context of an individual's genetics are areas that will open new horizons in the knowledge of mechanisms of gut inflammation.

REFERENCES

1 Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-6108 [PMID: 17036379]

2 Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83; quiz 464, 468 [PMID: 19174807 DOI: 10.1038/ajg.2008.168]

3 Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]

4 Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 204-211 [PMID: 9040192]

5 Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836 [PMID: 16143122 DOI: 10.1053/j.gastro.2005.06.021]

6 Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol 2012; 3: 13 [PMID: 22347192 DOI: 10.3389/fphys.2012.00013]

7 Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 2012; 18: 857-862 [PMID: 21739532 DOI: 10.1002/ibd.21805]

8 De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massari S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107: 14691-14696 [PMID: 20679230 DOI: 10.1073/pnas.1005963107]

9 Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011; 60: 49-54 [PMID: 20966024 DOI: 10.1136/gut.2010.219683]

10 Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Owuahend WH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskvina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop TD, Iles MM, Maqbool A, Yudashkev N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Omnie CM, Prescott NJ, Sanderson J, Matthew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop MG, Connell J, Dominiczak A, Marciano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hilder SL, Hinks AM, John SL, Potter C, Silman AJ, Symons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Frayling TM, Freathy RM, Lango H, Perry JR, Shields BM, Weedsen MN, Hattersley AT, Hitzman GA, Walker M, Elliott KS, Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, Newport M, Sirigo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon J, Wordsworth P, Brown MA, Franklin JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Stratton MR, Rahman N, Ban M, Goris A, Sawyer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Ioouye M, Keniry A, King E, McGinnes R, Potter S, Ravindrarajah R, Whittaker P, Widdenden C, Withers D, Cardin NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdottir IB, Howie BN, S Zu, Teo YY, Kucvek D, Bentley D, Brown MA, Compston A, Farrell M, Hall AS, Hattersley AT, Hill AV, Parkes M, Pembrey M, Stratton MR, Mitchell SL, Newby PR, Brand OJ, Carr-Smith J, Pearce SH, McGinnis R, Keniry A, Deloukas P, Revellie JD, Zhou X, Sims AM, Dowling A, Taylor J, Doan T, Davis JC, Savage L, Ward MM, Leach TL, Weismann MH, Brown M. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmune variants. Nat Genet 2007; 39: 1329-1337 [PMID: 17952073]

11 Duer RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barnama MM, Rotter JI, Nicolea DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463 [PMID: 17686223 DOI: 10.1126/science.1135245]

12 Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmado T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellingham D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Jarett EB, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumann P, Sharma Y, Simons LA, Taylor KD, Whiteman D, Wijnenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Bönning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Geary R, Glas J, Van Gossum A, Guthery SL, Hallvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Lübiolle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Demmaa K, Dupes K, Eathler K, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Anness V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-
analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. *Nat Genet* 2010; 42: 1118-1125 [PMID: 21024635 DOI: 10.1038/ng.717]

13 **Hampe J**, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Alfredsson L, Mayr G, De La Vega FM, Briggs J, Günthner S, Prescott NJ, Ommen CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 2007; 39: 207-211 [PMID: 17200669 DOI: 10.1038/ng1954]

14 **Bamias G**, Corridoni D, Pizzaro TT, Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. *Cytokine* 2012; 59: 451-459 [PMID: 22795953 DOI: 10.1016/j.jcyt.2012.06.014]

15 **Brandtzaeg P**. Mucosal immunity: induction, dissemination, and effector functions. *Scand J Immunol* 2009; 70: 505-515 [PMID: 19906191 DOI: 1113/365-3809.2009.02319.x]

16 **D’Haens GR**, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. *Gastroenterology* 1998; 114: 262-267 [PMID: 9433485]

17 **Casellas B**, Borrue N, Papo M, Guamer F, Antholin M, Videla S, Malagelada JR. Antimicrobial effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. *Inflamm Bowel Dis* 1998; 4: 1-5 [PMID: 9552221]

18 **Strober W**, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *J Clin Invest* 2007; 117: 514-521 [PMID: 17332878 DOI: 10.1126/science.1110591]

19 **Turnbaugh PJ**, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JJ. The human microbiome project. *Nature* 2007; 449: 804-810 [PMID: 17943116 DOI: 10.1038/nature06244]

20 **Eckburg PB**, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. *Science* 2005; 308: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.1110591]

21 **Caporaso JG**, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knight R, Fierer N, Gordon JJ, Knight R. Moving pictures of the human microbiome. *Genome Biol* 2011; 12: R50 [PMID: 21624126 DOI: 10.1186/gb-2011-12-5-r50]

22 **Qin J**, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tai J, Tang F, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarnier F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; 464: 59-65 [PMID: 20230630 DOI: 10.1038/nature08821]

23 **Arumugam M**, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandez GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gaultier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarnier F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolini M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner K, Folsch UR, Timmis KN, Schreiber S. Reduced diversity of faecal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 2011; 140: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]

24 **Sokol H**, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. *J Clin Microbiol* 2006; 44: 3172-3177 [PMID: 16954244 DOI: 10.1128/JCM.02600-05]

25 **Kang S**, Denman SE, Morrison M, Yu Z, Doré J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis* 2010; 16: 2034-2042 [PMID: 20848492 DOI: 10.1002/ibd.21319]

26 **Manichanh C**, Rigottier-Gois L, Boutte F, Pelletier E, Fierer N, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A. CEACAM6 acts as a receptor for adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. *Gastroenterology* 2009; 137: 2078-210 [PMID: 19769621 DOI: 10.1073/pnas.0706625104]

27 **Willing BP**, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tykkö C, Jansson J, Engstrand L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* 2010; 139: 1844-1854.e1 [PMID: 20746290 DOI: 10.1053/j.gastro.2010.08.049]

28 **Martinez-Medina AL**, Aldeguer X, Lopez-Siles M, Gonzalez-Huix F, Lopez-Olivo DA, Dabhi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease. *Inflamm Bowel Dis* 2009; 15: 872-882 [PMID: 19235912 DOI: 10.1002/ibd.20860]

29 **Darfeuille-Michaud A**. Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn’s disease. *Int J Med Microbiol* 2002; 292: 185-193 [PMID: 12398209 DOI: 10.1053/ijmm.2001.02001]

30 **Darfeuille-Michaud A**, Boudevau J, Bulos P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. *Gastroenterology* 2004; 127: 412-421 [PMID: 15305753]

31 **Barnich N**, Boudevau J, Clarlet L, Darfeuille-Michaud A. Regulatory and functional co-operation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn’s disease. *Mol Microbiol* 2003; 48: 781-794 [PMID: 12694621]

32 **Barnich N**, Carvalho FA, Glasser AL, Darcha C, Jantschel P, Allez M, Peeters H, Bommelaer G, Deseuxmaux P, Colombel JF, Darfeuille-Michaud A. CEACAM6 acts as a receptor for...
for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. *J Clin Invest* 2007; 117: 1566-1574 [PMID: 17525800 DOI: 10.1172/JCI30504]

37. *Carvalho FA*, Barnich N, Sivignon A, Darocha C, Chan CH, Stanners CP. Darfeuille-Michaud A. Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. *J Exp Med* 2009; 206: 2179-2189 [PMID: 19753864 DOI: 10.1084/jem.20090741]

38. *Glasser AL*, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. *Infect Immun* 2001; 69: 5529-5537 [PMID: 11504426]

39. *Lapaquette P*, Glasser AL, Huetta V, Xavier RJ, Darfeuille-Michaud A. Crohn’s disease-associated adherent-invasive E. coli are selectively favoured by impaired apoptosis to replicate intracellularly. *Cell Microbiol* 2010; 12: 99-113 [PMID: 19974213 DOI: 10.1111/j.1462-5822.2009.01381.x]

40. *Goodridge HS*, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss AS, Vasilakis JP, Underhill DM. Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. *Nature* 2011; 472: 471-475 [PMID: 21525931 DOI: 10.1038/nature10771]

41. *Iliev ID*, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, Rotter JJ, Wang HL, McGovern DP, Brown GD, Underhill DM. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science* 2012; 336: 1314-1317 [PMID: 22674328 DOI: 10.1126/science.1211799]

42. *Cadwall P*, Patel K, Maloney NS, Liu TC, Ng AC, Storer CE, Head KD, Xavier R, Stappenbeck TS, Vienna HW. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atd161L1 phenotypes in intestine. *Cell* 2010; 141: 1135-1145 [PMID: 20602997 DOI: 10.1016/j.cell.2010.05.009]

43. *Brenchley JM*, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bernard E, Lambotte O, Allman D, Blazar BR, Rodriguez B, Teixeira-Teixeira L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006; 12: 1365-1371 [PMID: 17115046 DOI: 10.1038/nm1511]

44. *Brenchley JM*, Douek DC. Microbial translocation across the GI tract. *Annu Rev Immunol* 2012; 30: 149-173 [PMID: 22224779 DOI: 10.1146/annurev-immunol-020711-075011]

45. *Estes JD*, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, Hirsch VM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. *PLoS Pathog* 2010; 6: e1001052 [PMID: 20888091 DOI: 10.1371/journal.ppat.1001052]

46. *Handley SA*, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley WM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. *PLoS Pathog* 2012; 8: 1002762 [PMID: 22842851 DOI: 10.1371/journal.ppat.1002762]

47. *Dieleman LA*, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis Dieleman LA, Kindberg E, Buesa J, Rydell GE, Lidón MF, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Se deficiency virus infection is associated with expansion of the enteric virome. *Cell Microbiol* 2006; 8: 1314-1317 [PMID: 16831596 DOI: 10.1053/j.gastro.2006.04.020]

48. *Van der Sluis M*, De Koning BA, De Bruijn AC, Velich A, Meijerink JP, Van Goudoever JB, Bäcker HA, Dekker J, Van Seuningen J, Renes IB, Eimerhand AW. Mu2-deficient mice spontaneously develop colitis, indicating that Mu2 is critical for colonic protection. *Gastroenterology* 2006; 131: 117-129 [PMID: 16151693 DOI: 10.1053/j.gastro.2005.10.041]

49. *Larsson JM*, Carlsson H, Crespo JG, Johansson ME, Eklund L, Stjövall H, Hansson GC. Altered O-glycosylation profile of Mu2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. *Inflamm Bowel Dis* 2011; 17: 2299-2307 [PMID: 21290483 DOI: 10.1002/ibd.21625]

50. *Blackwell CC*, Jonsdottir K, Hanson MF, Weir DM. Non-secretion of ABO blood group antigens predisposing to infection by Haemophilus influenzae. *Lancet* 1986; 2: 687 [PMID: 2876155]

51. *Blackwell CC*, Jonsdottir K, Hanson M, Todd WT, Chaudhuri AK, Mathew B, Brettle RP, Weir DM. Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae. *Lancet* 1986; 2: 284-285 [PMID: 2874307]

52. *Carlsson B*, Kindberg E, Buesa J, Rydell GE, Lidon MF, Montava R, Abu Mallouh R, Grahn A, Rodriguez-Diaz J, Bellido J, Amedo A, Larson G, Svensson L. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic G1L4 Norovirus infection. *PLoS One* 2009; 4: e5593 [PMID: 19440360 DOI: 10.1371/journal.pone.0005593]

53. *Kelly RJ*, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha[1,2]fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. *J Biol Chem* 1995; 270: 4640-4649 [PMID: 7876235]

54. *Marineauonne S*, Airaud F, Bovin NV, Le Pendi J, Ruvoen-Clouet N. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. *J Infect Dis* 2005; 192: 1071-1077 [PMID: 16107962 DOI: 10.1086/435264]

55. *McGovern DP*, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagace C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D’Amato M, Halfvarson J, Hibberd ML, Lordal M, Paydukov L, Andruilli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Skotters PC, Weersma RK, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dlugosky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Valiarskauska E, Targan SR, Annese V, Wijmenega C, Pettersson S, Rotter JJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet* 2010; 42: 332-337 [PMID: 20228799 DOI: 10.1038/ng.549]

56. *Thorven M*, Grahn A, Hellund KO, Johansson H, Wahlfrid C, Larson G, Svensson L. A homozygous nonsense mutation (428C–&gt;t;A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGI1) infections. *J Virol* 2005; 79: 15351-15355 [PMID: 16306606 DOI: 10.1128/JVI.79.24.15351-15355.2005]

57. *Pellekova VD*, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA. Functional variants of OCTN cation transporter genes are associ-
with susceptibility to Crohn’s disease. Nature 2001; 411: 599-603 [PMID: 11385576 DOI: 10.1038/sf0791007]

76 Levine B, Mizushima N, Virgin HW. Autophagy in infection and immunity. Nature 2011; 469: 323-335 [PMID: 22148859 DOI: 10.1038/nature09782]

77 Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kw C, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW. A key role for autophagy and the autophagy gene Atg16L1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259-263 [PMID: 18849966 DOI: 10.1038/nature07416]

78 Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97 [PMID: 19966812 DOI: 10.1038/nm.2069]

79 Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006; 313: 1438-1441 [PMID: 16888103 DOI: 10.1126/ science1129577]

80 Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huetta A, Green T, Kuballa P, Barnada MM, Datta LW, Shugart YY, Grifiths AM, Targan SR, Ippoliti AF, Bernard ME, Cel L, Nicolae DL, Reguero M, Schumum LP, Steinhart AH, Rotter JJ, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604 [PMID: 17435756 DOI: 10.1038/ng2032]

81 Spits H, Cupedo T. Innate lymphoid cells: emerging innsights in development, lineage relationships, and function. Annu Rev Immunol 2012; 30: 647-675 [PMID: 22247635 DOI: 10.1146/annurev-immunol-020711-070503]

82 Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasus S, Locksley RM, McKenzie AN, Mebius RE, Powrie F, Vivier E. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149 [PMID: 23348417 DOI: 10.1038/nri3365]

83 Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD, Zurawski G, Leach MW, Gorman DM, Rennick DM. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15: 985-995 [PMID: 11754819]

84 Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TB, Brieland JK, Zurawski SM, Chapman RW, Zurawski G, Coffman RL. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002; 169: 443-453 [PMID: 12077275]

85 Neill DR, Wong SH, Bellisi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464: 1367-1370 [PMID: 20205518 DOI: 10.1038/nature08900]

86 Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, Locksley RM. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010; 107: 11489-11494 [PMID: 20534524 DOI: 10.1073/pnas.1003888107]

87 Chang YJ, Kim HY, Albacker LA, Baumgath N, McKenzie AN, Smith DE, Dekroy RH, Umeto DT. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011; 12: 631-638 [PMID: 21623379 DOI: 10.1038/ni.2045]

88 Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, Angelosanto JM, Laidlaw BJ, Yang CY, Sathiyalayaala T, Kubota M, Turner D, Diamond JM, Goldrath AW, Farber DL, Collman RA, Wherry EJ, Artis D. Innate lymphoid cells promote lung-tissue homeostasis
117 Witowski J, Pawlaczuk K, Breborowicz A, Scheuera A, Kuzlan-Pawlaczuk M, Wisniewska J, Polubinska J, Triess H, Gahl GM, Frei U, Jörres A. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. *J Immunol* 2000; 165: 5814-5821 [PMID: 11067941]

118 Aherne PP, Schiering C, Buonocore S, McCahey MJ, Cua DJ, Maloy KJ, Powrie F. Interleukin-23 drives intestinal inflammation through direct activity on T cells. *Immunity* 2010; 33: 279-288 [PMID: 20732640 DOI: 10.1016/j.immuni.2010.08.010]

120 Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filli L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. *J Exp Med* 2007; 204: 1849-1861 [PMID: 17635957 DOI: 10.1084/jem.20070663]

121 Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angelì R, Berrino M, Littman DR, Hibi T. Regulatory T cells suppress development of colitis, blocking differentiation of Th17 cells. *Gastroenterology* 2011; 141: 1041-1023 [PMID: 21699791 DOI: 10.1053/j.gastro.2011.05.052]

122 Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 2003; 52: 65-70 [PMID: 12477762]

123 Kolls JK, Lindén A. Interleukin-17 family members and inflammation. *Immunity* 2004; 21: 467-476 [PMID: 15485625 DOI: 10.1016/S1074-7617(04)00081-3]

124 Sugihara T, Kobori A, Imaeda H, Tsujikawa T, Amagase K, Takeuchi K, Fujiyama Y, Andoh A. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. *Clin Exp Immunol* 2010; 160: 386-393 [PMID: 20889077 DOI: 10.1111/j.1365-2249.2010.04093.x]

125 Dambacher J, Beigel F, Zittmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. *Gut* 2009; 58: 1207-1217 [PMID: 18483078 DOI: 10.1136/gut.2007.130112]

126 Ghoreschi K, Laurencin A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux M, Granger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ. Generation of pathogenic T(H)17 cells in the absence of IL-23p40. *Nature* 2010; 467: 973-977 [PMID: 20962866 DOI: 10.1038/nature09947]

127 Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1Fc fusion protein. *Arthritis Rheum* 2002; 46: 802-805 [PMID: 11902418 DOI: 10.1002/art.10173]

128 Komiya Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Sakata S, Sudo K, Ikawa Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. *J Immunol* 2006; 177: 556-573 [PMID: 16785554]

129 Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. *Inflamm Bowel Dis* 2006; 12: 382-388 [PMID: 16673522 DOI: 10.1097/01.MIB.0000218764.00009.91]

130 Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. *Cytokine Growth Factor Rev* 2003; 14: 155-174 [PMID: 12651226]

131 O'Connor W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. *Nat Immunol* 2010; 10: 603-609 [PMID: 19484631 DOI: 10.1038/ni.1736]

132 Sara M, Pallone F, Macdonald TT, Monteleone G. IL-23-17 axis in IBD. *Inflamm Bowel Dis* 2010; 16: 1808-1813 [PMID: 20222127 DOI: 10.1002/ibd.21248]

133 Awasthi A, Kuchroo VK. IL-17A directly induces TH1 cells and thereby suppresses development of intestinal inflammation. *Nat Immunol* 2009; 10: 568-570 [PMID: 19448657 DOI: 10.1038/ni0609-568]

134 Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. *Clin Immunol* 2011; 140: 55-62 [PMID: 19462796 DOI: 10.1016/j.clim.2011.03.013]

135 Hueber W, Sands BE, Lewitsky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkmaj, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Buc, Brin G, Mellgård B, Berger C, Lonedi M, Bertolino AP, Tough G, Travis SP, Sekuinubam, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut* 2012; 61: 1693-1700 [PMID: 22593513 DOI: 10.1136/gutjnl-2011-301668]

136 Cassatella MA, Pereira-da-Silva G, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulates monocytes in rheumatoid arthritis. *J Immunol* 2007; 178: 7325-7333 [PMID: 17513783]

137 Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ulbrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore FA, Ruben SM, Wei P. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. *Immunology* 2002; 107: 479-492 [PMID: 11911831]

138 Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. *J Immunol* 2007; 178: 4033-4038 [PMID: 17571957]

139 Shih DQ, Kwan LW, Chavez V, Cohavy O, Gonsky R, Chang EY, Chang C, Elson CO, Targan SR. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. *Eur J Immunol* 2009; 39: 3239-3250 [PMID: 19839006 DOI: 10.1002/eji.200839087]

140 Screenshot GR, Xu XN, Olsen AL, Cowper AE, Tan R, McMichael AJ, Bell JI. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. *Proc Natl Acad Sci USA* 1997; 94: 4615-4619 [PMID: 9114039]

141 Barrett R, Zhang X, Koon HW, Yu M, Chang JY, Yeager N, Nguyen MA, Michelsen KS, Berel D, Potthoulakis C, Targan SR, Shih DQ. Constitutive TL1A expression under colitigenic conditions modulates the severity of gut mucosal inflammation and induces fibrostenosis. *Am J Pathol* 2012; 180: 636-649 [PMID: 22138299 DOI: 10.1016/j.ajpath.2011.10.026]

142 Shih DQ, Barrett R, Zhang X, Yeager N, Koon HW, Phaosawad P, Song Y, Ko B, Wong MH, Michelsen KS, Martins
Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. *PLoS One* 2011; 6: e16690 [PMID: 21264313 DOI: 10.1371/journal.pone.0016690]

Zheng L, Zhang X, Chen J, Ichikawa R, Wallace K, Pothoulakis C, Koon HW, Targan SR, Shih DQ. Sustained TL1A (TNFSF15) expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis. *Eur J Microbiol Immunol* (Bp) 2013; 3: 11-20 [PMID: 23638306 DOI: 10.1556/EuMi.3.2013.1.2]

Meylan F, Richard AC, Siegel RM. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. *Immunol Rev* 2011; 244: 188-196 [PMID: 22017439 DOI: 10.1111/j.1600-065X.2011.01068.x]

Meylan F, Song YJ, Fuss I, Villareal S, Kahle E, Malm IJ, Acharya K, Ramos HL, Lo L, Mentink-Kane MM, Wynn TA, Migone TS, Strober W, Siegel RM. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. *Mucosal Immunol* 2011; 4: 172-185 [PMID: 20980995 DOI: 10.1038/mi.2010.67]

Taranan VY, Slebioida TJ, Willoughby JE, Buchan SL, James S, Sheth B, Smyth NR, Thomas GJ, Wang EC, Al-Shamkhani A. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. *Mucosal Immunol* 2011; 4: 186-196 [PMID: 20962771 DOI: 10.1038/mi.2010.70]

Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. *Hum Mol Genet* 2005; 14: 3499-3506 [PMID: 16221758 DOI: 10.1093/hmg/ddi379]

Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. *Gut* 2006; 55: 1527-1528 [PMID: 16966713 DOI: 10.1136/gut.2006.100297]

Piconell Y, Mei L, Taylor K, Yang H, Targan SR, Rotter JI. TNFSF15 is an ethnic-specific IBD gene. *Inflamm Bowel Dis* 2007; 13: 1333-1338 [PMID: 17663424 DOI: 10.1002/ibd.20233]

Thiébaut R, Kotti S, Jung C, Merlin F, Colombel JF, Lemann M, Almer S, Tsyk C, O’Morain M, Gassull M, Binder V, Finkel Y, Pascoe L, Hugot JP. TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. *Am J Gastroenterol* 2009; 104: 384-391 [PMID: 19174806 DOI: 10.1038/ajg.2008.36]

Tremelling M, Berzuini C, Massey D, Bredin F, Price C, Dawson C, Bingham SA, Parkes M. Contribution of TNFSF15 gene variants to Crohn’s disease susceptibility confirmed in UK population. *Inflamm Bowel Dis* 2008; 14: 733-737 [PMID: 18388767 DOI: 10.1002/ibd.20399]

Yang SK, Lim J, Chang HS, Lee J, Li Y, Jiang K. Association of TNFSF15 with Crohn’s disease in Koreans. *Am J Gastroenterol* 2008; 103: 1437-1442 [PMID: 18422820 DOI: 10.1111/j.1572-0241.2007.01752.x]

Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. *Am J Gastroenterol* 2004; 99: 2376-2384 [PMID: 15571586 DOI: 10.1111/j.1572-0241.2004.0417.x]

Mow WS, Vasiliasouka EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martín MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. *Gastroenterology* 2004; 126: 414-424 [PMID: 14762777]

Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ, Derkowska C, McGovern DP, Rotter JI, Targan SR. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. *PLoS One* 2009; 4: e4719 [PMID: 19262684 DOI: 10.1371/journal.pone.0004719]

Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. *Gastroenterology* 2008; 135: 552-567 [PMID: 18598698 DOI: 10.1053/j.gastro.2008.04.037]

Dardalhon V, Avasthi A, Kwon H, Galilleos G, Gao W, Sobel RA, Mitsuorffer M, Strom TB, Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. *Immunity* 2010; 33: 573-585 [PMID: 19920355 DOI: 10.1016/j.immuni.2009.05.001]

Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosega wa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. *Gut* 2006; 55: 1527-1528 [PMID: 16966713 DOI: 10.1136/gut.2006.100297]

King C, Sprent J. Emerging cellular networks for regulation of T follicular helper cells. *Trends Immunol* 2012; 33: 59-65 [PMID: 22209178 DOI: 10.1016/j.it.2011.11.006]

Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. *Annu Rev Immunol* 2004; 22: 531-562 [PMID: 15032588 DOI: 10.1146/annurev.immunol.21.120601.141122]

Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. *Immunity* 2009; 30: 646-655 [PMID: 19461987 DOI: 10.1016/j.immuni.2009.05.001]
